RICARDO-PLC
Ricardo plc, a global strategic, environmental and engineering consulting company, today announces the acquisition of a 93% shareholding of E3-Modelling S.A., a consultancy specialising in delivering advanced empirical modelling of the energy-economy-environment nexus.
E3M’s 34-strong team develops and maintains large-scale models across the energy, environment and transport sectors. Its expertise focuses on the design and impact analysis of the transition of all possible types of power generation technologies, several types of alternative green fuels, energy demand efficiency and mobility restructuring, taking into account the impact of major energy policies on the economies of European countries and globally, with details for more than 50 economic activities. Its integrated modelling tools provide informed, transparent and robust analysis as well as recommendations for its high-profile clients which include the European Commission, national governments, energy regulators and a number of private companies in the energy and transport sectors, financial institutions and strategic consultancies.
Over the past 30 years, E3-Modelling has carried out consultancy on all major European energy and climate policy initiatives, and its large-scale energy, economy and transport models have been applied at the very heart of European Commission policymaking.
“Ricardo’s acquisition of E3-Modelling is fully aligned with our ambition to become a global leader in strategy and engineering consultancy for environmental and energy-transition solutions.” said, Graham Ritchie, Ricardo CEO. “It provides an opportunity to deliver repeatable digital models focused on energy markets, climate change and the decarbonisation of transport to governments and corporate clients globally. We already have a strong working relationship with E3-Modelling having worked together for over 10 years, and this acquisition is a natural advancement, combining our skillsets to offer a transformational contribution to Ricardo’s energy and environmental services portfolio.”
Prof. Emeritus Pantelis Capros and Dr. Leonidas Paroussos of E3-Modelling S.A. added: "We are very excited to be joining an energy & environmental consultancy of Ricardo’s pedigree and to see the business we've built embark on its next stage of growth. By leveraging Ricardo’s scale and resources, we will be able to expand our reach beyond Europe and broaden our modelling services as we assess the implications of energy, climate and sustainable development policies for our clients.”
E3M provides digital modelling capabilities right across the markets that Ricardo serves, making the acquisition highly complementary to Ricardo’s unique position at the intersection of the energy, environment and mobility agendas. To date, the use of E3M’s models has largely focused on Europe and neighbouring countries. The combination of E3M’s capabilities and expertise with Ricardo’s global footprint, services and diversified market expansion will support the Group in creating additional value for its global client base that are focused on their transition towards a low-carbon future.
~ENDS~
About Ricardo
Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and close to 3,000 colleagues in more than 20 countries, we provide exceptional levels of expertise in delivering innovative cross-sector sustainable outcomes to support energy transition and scarce resources, environmental services together with safe and smart mobility. Our global team of consultants, environmental specialists, engineers and scientists support our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
About E3-Modelling
E3-Modelling is a société anonyme (S.A.) company, established in Greece, as a knowledge-intensive consulting company. We deliver consulting services based on the large-scale empirical modelling of the economy-energy-environment nexus: PRIMES, GEM-E3 and Prometheus. We focus on the design of transition in the energy market and systems, both demand and supply of energy, towards green and climate-friendly structures and technologies. With the modelling, we help to assess the transitions from economic, policy and implementation perspectives putting emphasis on the functioning of the system and the markets as a whole when policy instruments influence behaviours and market outcomes. Visit www.e3modelling.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005530/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom